Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ALX40-4C antiviral: Began a Phase I/II trial in 40 patients to assess anti-CMV effect by viral load and measures of immune status. Groups of eight patients will

Allelix Biopharmaceuticals Inc. (TSE:AXB), Toronto
Product:

Read the full 62 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE